The last major penicillin plant in Europe is facing significant threats due to the influx of cheaper antibiotics from China. This situation raises concerns about potential drug shortages across the continent should the plant be forced to close. Increased competition from Chinese suppliers is making it difficult for the European facility to remain economically viable. Dependence on imports, particularly from China, could leave Europe vulnerable in pharmaceutical supply chains. Experts warn that relying solely on foreign production presents risks to public health security. The future of antibiotic production within Europe hangs in the balance as the plant struggles to compete with lower-priced alternatives. This highlights a broader issue of European industrial competitiveness in essential medicine manufacturing.